CRDF (Cardiff Oncology) Treasury Stock: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $0.89
GF Value $1.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Treasury Stock?

Cardiff Oncology CRDF -33.63% 48 Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Cardiff Oncology's treasury stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Cardiff Oncology Treasury Stock Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Treasury Stock Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CRDF
48GF Score
Cardiff Oncology Inc CRDF
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Cardiff Oncology (CRDF) has a Treasury Stock of $0.00 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Cardiff Oncology and its competitors.
Is Cardiff Oncology's Treasury Stock too high?
Cardiff Oncology's current Treasury Stock is $0.00 Mil. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Treasury Stock compare to MAIA and TELO?
Cardiff Oncology's Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Cardiff Oncology and its competitors. Cardiff Oncology's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.40, compared to a current price of $0.89 — trading 36.4% below its estimated fair value. The current Treasury Stock is $0.00 Mil. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $0.89 is trading 36.4% below its estimated GF Value™ of $1.40. GuruFocus considers Cardiff Oncology to be Possible Value Trap.

Key valuation signals for CRDF:

  • Treasury Stock: $0.00 Mil
  • GF Value™: $1.40 vs. price of $0.89 (36.4% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.89
Price
$1.40
GF Value